Alkermes plc (NASDAQ:ALKS – Get Rating) COO Blair Curtis Jackson sold 49,999 shares of the stock in a transaction that occurred on Wednesday, April 20th. The stock was sold at an average price of $29.61, for a total value of $1,480,470.39. Following the sale, the chief operating officer now directly owns 87,915 shares of the company’s stock, valued at $2,603,163.15. The transaction was disclosed in a filing with the SEC, which is accessible through this link.
NASDAQ ALKS opened at $28.20 on Friday. The company has a market cap of $4.61 billion, a PE ratio of -94.00 and a beta of 0.90. The company has a current ratio of 2.25, a quick ratio of 1.93 and a debt-to-equity ratio of 0.26. Alkermes plc has a 12 month low of $20.76 and a 12 month high of $33.00. The stock has a 50 day moving average of $26.41 and a 200-day moving average of $25.78.
Alkermes (NASDAQ:ALKS – Get Rating) last released its quarterly earnings data on Wednesday, February 16th. The company reported $0.13 EPS for the quarter, beating the consensus estimate of ($0.03) by $0.16. The company had revenue of $324.50 million during the quarter, compared to the consensus estimate of $306.55 million. Alkermes had a positive return on equity of 3.95% and a negative net margin of 4.10%. The firm’s revenue for the quarter was up 15.9% compared to the same quarter last year. During the same quarter in the prior year, the firm posted ($0.05) EPS. As a group, sell-side analysts predict that Alkermes plc will post -0.6 EPS for the current fiscal year.
A number of analysts recently issued reports on the company. Mizuho increased their target price on Alkermes from $33.00 to $35.00 in a research note on Thursday, February 17th. TheStreet raised Alkermes from a “d+” rating to a “c” rating in a research report on Tuesday, March 1st. StockNews.com raised Alkermes from a “buy” rating to a “strong-buy” rating in a research report on Wednesday, April 13th. SVB Leerink upped their price target on Alkermes from $24.00 to $25.00 and gave the stock a “market perform” rating in a research report on Thursday. Finally, Zacks Investment Research raised Alkermes from a “hold” rating to a “strong-buy” rating and set a $28.00 price target for the company in a research report on Monday, January 10th. One analyst has rated the stock with a sell rating, five have given a hold rating, three have assigned a buy rating and two have given a strong buy rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Buy” and an average price target of $30.30.
Alkermes Company Profile (Get Rating)
Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the United States, Ireland, and internationally. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; VIVITROL for the treatment of alcohol and prevention of opioid dependence; RISPERDAL CONSTA for the treatment of schizophrenia and bipolar I disorder; INVEGA SUSTENNA for the treatment of schizophrenia and schizoaffective disorder; XEPLION, INVEGA TRINZA, and TREVICTA to treat schizophrenia and schizoaffective; and VUMERITY for the treatment of relapsing forms of multiple sclerosis in adults, including clinically isolated syndrome, relapsing-remitting and active secondary progressive diseases.
- Get a free copy of the StockNews.com research report on Alkermes (ALKS)
- 3 Resilient Stocks to Buy for Retirement
- MarketBeat: Week in Review 4/18 – 4/22
- Tractor Supply Company Reaps What It Sows
- Snap (NYSE: SNAP) Gives Investors A Mixed Bag
- Should You Buy Carvana or AutoNation or Pass on Both?
Receive News & Ratings for Alkermes Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alkermes and related companies with MarketBeat.com's FREE daily email newsletter.